Medivation shelves Dimebon in Huntington's after Phase III failure, putting a damper on AD programme
This article was originally published in Scrip
Executive Summary
Medivation is halting the development of its investigational agent Dimebon (latrepiridine) in Huntington's disease, a genetic progressive brain disorder, after top-line data from the company’s 403-patient Phase III HORIZON trial showed no statistically significant improvements versus placebo on either of two co-primary endpoints. The drug is being co-developed with Pfizer.